共查询到20条相似文献,搜索用时 93 毫秒
1.
内皮抑素(endostatin)是近年来发现的,天然产生的新血管生成抑制因子。它在体内由胶原ⅩⅧ经酶解产生,可以抑制新血管生成,在肿瘤动物模型中显示出显著的抑瘤活动。通过抑制肿瘤相关的新血管的形成来治疗肿瘤,是目前出现的新疗法,内皮抑素是这种疗法中很有前景的侯选药物之一。在美国已经开始了用内皮抑素治疗肿瘤的Ⅰ期临床试验,关于它的临床前基础实验也在广泛开展。本文综述了内皮抑素在肿瘤治疗中的应用基础研究 。 相似文献
2.
肿瘤生长抑制因子—血管抑素和内皮抑素 总被引:1,自引:0,他引:1
血管生成是肿瘤生长转移过程中的一个关键环节,因此控制血管生成成为抑制肿瘤生长的重要途径之一。目前已发现了许多血管生成抑制因子,尤以血管抑素和内皮抑素最为引人瞩目。综述了两种肿瘤生长抑制因子的发现、分子结构、生物学活性等,尤其侧重于它们抗肿瘤作用的实验研究。血管抑素与内皮抑素的发现与研究为恶性肿瘤的治疗开辟了新的道路。 相似文献
3.
血管抑素是第一个被发现的肿瘤源性血管生成抑制因子,能抑制血管内细胞的增殖和迁移,从而抑制肿瘤的生长。通过一些实验方法能够检测肿瘤患者体内的血管抑素水平。血管抑素在未来的肿瘤治疗、诊断、预后判断和新生血管疾病的治疗中有着广阔的应用前景。 相似文献
4.
血管抑素是第一个被发现的肿瘤源性血管生成抑制因子,能抑制血管内细胞的增殖和迁移,从而抑制肿瘤的生长。通过一些实验方法能够检测肿瘤患者体内的血管抑素水平。血管抑素在未来的肿瘤治疗、诊断、预后判断和新生血管疾病的治疗中有着广阔的应用前景。 相似文献
5.
6.
人肿瘤抑素(Tumstatin)在E.coli中的克隆、表达及活性分析 总被引:1,自引:0,他引:1
从人胚肾2 93细胞中扩增肿瘤抑素(tumstatin)基因,进行原核表达,纯化和生物活性检测.利用原核表达载体pMAL c2在大肠杆菌BL2 1中表达肿瘤抑素,经AmyloseResin亲和层析柱和QSepharoseFastFlow柱纯化,通过体外内皮细胞增殖、内皮细胞凋亡和鸡尿囊绒膜新生血管生成试验检测其抑制活性.MBP tumstatin在BL2 1中表达率约2 0 % ,肿瘤抑素纯度可达95 % .肿瘤抑素可明显抑制内皮细胞增殖(IC50 约为15 μg ml)、诱导内皮细胞凋亡和抑制鸡尿囊绒膜新生血管生成.研究结果表明,肿瘤抑素对内皮细胞具有明显的抑制作用,提示其在肿瘤治疗中有潜在的应用前景. 相似文献
7.
8.
9.
源于Ⅳ型胶原α3、α6链的肿瘤新生血管生成抑制剂 总被引:1,自引:0,他引:1
肿瘤抑素(Tumstatin)和Hexastatin是分别源于Ⅳ型胶原α3、α6链的肿瘤新生血管生成抑制剂.肿瘤的发生、发展和转移都依赖于新生血管的生成.通过抑制肿瘤新生血管的生成,阻断肿瘤细胞赖以生存的氧气及营养供给,肿瘤细胞便会发生凋亡.这是肿瘤治疗的新策略.Tumstatin和Hexastatin是近年来研究比较多的两种肿瘤新生血管生成抑制剂,其中Tumstatin的结构、活性位点、抑制肿瘤新生血管形成机制研究得比较清晰;Hexastatin虽与Tumstatin有许多相似之处,但是还有很多问题需要进一步研究解决.该文就这两种肿瘤新生血管生成抑制剂等的最新研究进展做一综述. 相似文献
10.
血管生成抑制素作用机理的研究进展 总被引:1,自引:0,他引:1
血管生成抑制素(angiostatin)是纤溶酶原(plasminogen)在体内的天然水解产物,能够有效抑制血管内皮细胞的增殖、迁移和管状结构的形成而参与对血管生成过程(angiogenesis)的调节。血管生成是指从已经存在的血管生长出新的分枝血管的过程。该过程在成体组织并不活跃,然而在某些病理条件下如伤口愈合、炎症、肿瘤的生长和恶性转移时却常常伴随活跃的血管生成过程。血管生成抑制素对血管生成的抑制作用,提示其作为一种特异性的针对血管内皮细胞的药物治疗与血管生成有关的一些疾病,如肿瘤的可能性。本文主要介绍近年来关于Angiostatin作用机理的研究进展以及其作为治疗药物的应用前景。 相似文献
11.
Recombinant mouse canstatin inhibits chicken embryo chorioallantoic membrane angiogenesis and endothelial cell proliferation 总被引:7,自引:0,他引:7
Hou WH Wang TY Yuan BM Chai YR Jia YL Tian F Wang JM Xue LX 《Acta biochimica et biophysica Sinica》2004,36(12):845-850
It is now well documented that the growth and meta-stasis of malignant tumors beyond a few mm3 dependlargely upon the formation of networks known as angio-genesis [1–3]. Several studies have shown that the tumormass can be restricted to within a certain … 相似文献
12.
Kamphaus GD Colorado PC Panka DJ Hopfer H Ramchandran R Torre A Maeshima Y Mier JW Sukhatme VP Kalluri R 《The Journal of biological chemistry》2000,275(2):1209-1215
We isolated and identified an endogenous 24-kDa human basement membrane-derived inhibitor of angiogenesis and tumor growth, termed canstatin. Canstatin, a fragment of the alpha2 chain of type IV collagen, was produced as a recombinant molecule in Escherichia coli and 293 embryonic kidneys cells. Canstatin significantly inhibited human endothelial cell migration and murine endothelial cell tube formation. Additionally, canstatin potently inhibited 10% fetal bovine serum-stimulated endothelial cell proliferation and induced apoptosis, with no inhibition of proliferation or apoptosis observed on non-endothelial cells. Inhibition of endothelial proliferation was not concomitant with a change in extracellular signal-regulated kinase activation. We demonstrate that apoptosis induced by canstatin was associated with a down-regulation of the anti-apoptotic protein, FLIP. Canstatin also suppressed in vivo growth of large and small size tumors in two human xenograft mouse models with histology revealing decreased CD31-positive vasculature. Collectively, these results suggest that canstatin is a powerful therapeutic molecule for suppressing angiogenesis. 相似文献
13.
Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth 总被引:9,自引:0,他引:9
He GA Luo JX Zhang TY Wang FY Li RF 《Biochemical and biophysical research communications》2003,312(3):801-805
Type IV collagen is one of the components of vascular basement involved in regulation of angiogenesis. Canstatin, the non-collagenous 1 (NC1) domain of alpha2 chain of type IV collagen, was identified as an inhibitor of angiogenesis and tumor growth by Kamphaus et al. Our previous studies showed that canstatin-N, the N-terminal 1-89 amino acid fragment of canstatin, inhibited the neovascularization in a dose-dependent manner as tested by CAM assay. In the present study, we demonstrate that canstatin-N produced in Escherichia coli specifically inhibited in vitro the proliferation of human umbilical vein endothelial cells (ECV304) and significantly induced apoptosis. The apoptosis-inducing activity of canstatin-N was much stronger than that of canstatin, indicating that the apoptosis-inducing activity of canstatin is likely located within its N-terminal 1-89 amino acid fragment. Canstatin-N also suppressed in vivo growth of B(16) murine melanoma in BALB/c mice at a dosage of 10mg/kg/day. These results suggest that canstatin-N is a useful candidate molecule for inhibition of tumor growth. 相似文献
14.
小鼠canstatin及其N端片段在大肠杆菌BL21 中的表达 总被引:2,自引:0,他引:2
以小鼠肝脏组织总RNA为模板,通过RT-PCR扩增小鼠canstatin及其N端片段基因,克隆到pMD18-T载体中并进行序列分析。将小鼠canstatin及其N端片段基因定向克隆于原核表达载体pET30a(+)中,分别构建表达质粒pET/Can和pET/Can-N, 转化大肠杆菌BL21(DE3), IPTG诱导表达。结果表明: 小鼠canstatin的cDNA长度为684bp,编码227个氨基酸,与已知的人canstatin cDNA同源性为89%,氨基酸的同源性为96%。小鼠canstatin N端片段(1-95aa)与人的同源性为100%。 IPTG诱导原核表达载体pET/Can和pET/Can-N在大肠杆菌 BL21(DE3)中的表达量约占菌体总蛋白量的35% 和 18%, 重组蛋白主要以包涵体形式存在。文中报道的小鼠canstatin 及其N端片段核苷酸序列已收入GenBank, 接受号分别为: AY375463和AY502946。Abstract:The mouse canstatin and its N-domain cDNA were amplified from total RNA of mouse liver by RT- PCR and cloned into vector pMD18-T for sequencing. Prokaryotic expression vectors pET/Can and pET/Can-N were constructed and expressed in E.coli BL21(DE3) with induction of IPTG.. Mouse canstatin cDNA is 684bp in length encoding 227 amino acids. The sequences of both cDNA and amino acids share high homology with human canstatin, with cDNA identity at 89% and amino acids identity at 96% to human canstatin. N-domain of mouse canstatin is the same amino acid sequence as that of human canstatin. In the present study, prokaryotic expression vector pET/Can and pET/Can-N were expressed in E.coli BL21 with amount of 35% and 18% of the total bacterial proteins after being induced by IPTG for 4h. The expressed products existed mainly as inclusion bodies. This work has laid down the basis for further study of its angiogenic activity and potential application for tumor dormancy therapy. 相似文献
15.
为了研究重组小鼠canstatin N端片段的体内抗血管生成活性, 通过PCR扩增小鼠canstatin N端片段cDNA,定向克隆于原核表达载体pET30a(+)中,构建小鼠canstatin N端片段重组表达载体pET-mCanN, 转化E.coli BL21(DE3), IPTG诱导表达,SDS-聚丙烯酰胺凝胶电泳(SDS-PAGE)和蛋白质印迹检测小鼠canstatin N端片段的表达. 结果表明,IPTG诱导原核表达载体pET-mCanN在大肠杆菌E.coli BL21(DE3)中高效表达, 小鼠canstatin N端片段表达量约占菌体总蛋白量的18%, 小鼠canstatin N端片段主要以包涵体形式存在,包涵体经过洗涤、裂解、Ni-spin column亲合柱层析以及蛋白质复性等步骤纯化后,获得了纯度约为92%的重组小鼠canstatin N端片段. 鸡胚绒毛尿囊膜(chicken embryo choriollantoic membrane,CAM)实验表明,原核表达的小鼠canstatin N端片段能有效地按剂量依赖的方式抑制鸡胚新生血管的形成. 相似文献
16.
人血管能抑素基因的克隆、表达及其表达产物的纯化和生物活性测定 总被引:5,自引:0,他引:5
以人胎盘脐带组织为材料,提取组织总RNA,用netRTPCR方法合成人血管能抑素cDNA基因,将该cDNA克隆进pSP72载体获得重组质粒pSP72C, DNA序列分析结果与预期序列一致。用BamHⅠ和NdeⅠ双酶切,切下pSP72C上的血管能抑素cDNA,插入pET3c载体的相应位点获得重组表达质粒pETC, 转化E. coli BL21(DE3), SDSPAGE分析显示:在IPTG诱导下,血管能抑素基因获得了高效表达,表达量约占菌体总蛋白的 27.9 %,主要以包涵体形式存在。包涵体经过洗涤、裂解、蛋白复性以及Sephadex G75凝胶过滤层析等步骤后,获得了纯度达91.4 %的人血管能抑素。CAM实验证明10 μg纯化蛋白就能显著抑制鸡胚新生血管生成。 相似文献
17.
整合素αvβ3是一种能特异性识别RGD序列的膜受体蛋白,其与含RGD(Arg-Gly-Asp)模体的蛋白质结合的特异性在肿瘤细胞的粘附、迁移、浸润及肿瘤血管新生中起重要作用.由于整合素αvβ3在多种肿瘤细胞表面高表达而在正常细胞中低表达或不表达,因此其成为肿瘤治疗的理想靶点.肿瘤新生血管为肿瘤的生长提供营养,因此近年来抑制肿瘤血管新生也成为肿瘤治疗的重要途径.有研究显示,几种RGD毒素蛋白不但以整合素αvβ3为靶点靶向结合到肿瘤部位从而具有直接抗肿瘤细胞增殖、黏附、迁移及浸润功能,而且它们还具有抗肿瘤血管新生的作用,因此RGD毒素蛋白可从上述两方面抑制肿瘤生长与转移.本文就整合素αvβ3为靶向的RGD配体结构特点及其在肿瘤治疗中的靶向治疗和抗血管新生应用及前景加以综述. 相似文献
18.
The inhibitory effect of recombinant canstatin on tumor growth was investigated using an orthotopic oral squamous cell carcinoma
(AT-84 cells) animal (C3H/HeN) model. Recombinant canstatin from stably transfected Drosophila S2 cells was purified to homogeneity using a simple one-step Ni NTA affinity fractionation. In our oral cancer model, the
final volume and weight of tumors in groups treated with purified canstatin were both reduced to 44% of values for a control
group treated with PBS. Blood or lymphatic vessel densities of tumors in the canstatin-treated group were reduced to 72% and
44% of control group values, respectively. Recombinant canstatin at 20 μg/ml effectively inhibited tube formation in HUVEC
and lymphatic endothelial cells. Our results show that recombinant canstatin has anti-tumoral effects against primary oral
squamous cell carcinoma. 相似文献
19.
Angiogenesis or the generation of new blood vessel, is an important factor in the growth of a solid tumor. Hence, it becomes a necessary parameter of any kind of therapeutic study. Glutamine is an essential nutrient of tumor tissue and glutamine related therapy involves clearance of circulatory glutamine by glutaminase. Therefore, using different murine solid tumor models, the present study was undertaken to find out whether the S-180 cell glutaminase has any effect on angiogenesis of solid tumor, or not. Result indicates that the purified S-180 cell glutaminase reduces tumor volume and restrict the generation of neo blood vessels. Therefore, it can be concluded that this enzyme may be an effective device against the cancer metastasis. 相似文献
20.
The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells 总被引:12,自引:0,他引:12
He GA Luo JX Zhang TY Hu ZS Wang FY 《Biochemical and biophysical research communications》2004,318(2):354-360
Angiogenesis is crucial for the growth and metastasis of solid tumors with sizes larger than a few cubic millimeter Canstatin, the non-collagenous 1 (NC1) domain of alpha2 chain of type IV collagen, was previously shown to inhibit proliferation of endothelial cells in vitro and suppress in vivo tumor growth. Our previous studies showed that canstatin-N, the N-terminal 1-89 amino acid fragment of canstatin, inhibited the neovascularization in vivo, potently induced apoptosis of endothelial cells in vitro, and suppressed in vivo tumor growth in BALB/c mice. In the present study, we demonstrated that canstatin-C, the C-terminal 157-227 amino acid fragment of canstatin, also specifically inhibited in vitro the proliferation of human umbilical vein endothelial cells and induced apoptosis, but the apoptosis-inducing activity, while close to that of the full-length canstatin, was much lower than that of canstatin-N. Canstatin-C also suppressed in vivo tumor growth in BALB/c mice at a dosage of 10mg/kg/day. These results suggest that canstatin-C is an anti-angiogenic domain of canstatin mainly associated with the specific inhibition of proliferation of endothelial cells, whereas canstatin-N with the potential apoptosis-inducing activity on endothelial cells. 相似文献